

Second Quarter 2012 Earnings Release

Agenda







☐ Dial toll—free: 855.859.2056

☐ International: 404.537.3406

☐ Conference ID: #40917655

☐ Log on to: www.idexcorp.com







Cautionary Statement

Under the Private Securities

Litigation Reform Act

This presentation and discussion will include forward-looking statements. Our actual performance may differ materially from that indicated or suggested by any such statements. There are a number of factors that could cause those differences, including those presented in our most recent annual report and other company filings with the SEC.




Global Deceleration

- Strong first quarter followed by slowing second quarter
- North America remains strong for industrial and infrastructure-related markets
- Weak demand in Europe and slowing growth in China
- Growth rates in 2H will slow modestly
- Exceptional Operating Performance in Attractive Market Segments
- > Defensible diversified business with strong global teams delivering exceptional value
- Execution: operating margin expansion with laser focus on cash conversion
- Strong balance sheet and disciplined approach to deployment of capital
- IOP Challenged HST Performance
- Uncertainty in several OEM end markets
- CVI restructuring continues through year-end


Innovation New Products New Markets Acquisitions Operational
Excellence
Commercial
Excellence
Conversion

Growth



^{*} EPS / Op Margin data adjusted for \$2.6M restructuring expense (2012) and \$3M CVI inventory step-up expense (2011)





Q2 Sales Mix: Organic +3%	Q2 Summary:
A i - i - i - i	☐ Order softness experienced in Europe and China
Acquisition	☐ Energy, Chemical, Ag strong in NA and emerging markets
Fx <u>-2%</u>	☐ Water / Waste water outlook improving in NA, while still challenged internationally
Total +1%	☐ 2H market environment will be volatile: expecting continued slower markets

^{*} Op Margin data adjusted for restructuring expense (2012)





Q2 Sales Mix: Organic	+3%	Q2 Summary:
		☐ Acquired Matcon LTD (Material Process Technology "MPT" Platform)
Acquisi	tion +19%	☐ MPT platform performed well, driven by strong demand for food and pharma processing equipment (particularly in Asia)
Fx	<u>-1%</u>	☐ Scientific Fluidics experiencing market softness on inconsistent OEM demand
Total +21		☐ Optics end markets challenged; right-sizing the business for the bottom of the cycle
		☐ Excluding acquisitions, Op margins expanded modestly

^{*} Op Margin data adjusted for restructuring expense (2012) and \$3M CVI inventory step-up expense (2011) IDEX Proprietary & Confidential





Q2 Sales Mix: Organic +	15%	Q2 Summary:
Acquisition	-	□ North American Fire markets stabilized, now growing through adjacencies □ Fire restructuring activities will begin to provide benefit in FY13
Fx	<u>-5%</u>	 □ Rescue continues to win internationally despite headline challenges □ Dispensing initiated delivery on large replenishment order; domestic markets
Total +	Total +10% improving while European markets and open margins are up 50 bps excludi	

^{*} Op Margin data adjusted for restructuring expense (2012)



	FY12		
	Revenue	Adjusted EPS	
April 2012 - Prior Guidance	~\$2.0 B	\$2.80 - \$2.85	
Q2 miss (Compared to midpoint of prior guidance)	(15)	(0.04)	
Slower 2H Organic / Cost actions	(30)	(0.06)	
Optics (Challenging end markets)	(10)	(0.04)	
Fx impact	(20)	(0.03)	
ERC acquisition impact	15	0.02	
July 2012 - Revised Guidance	~\$1.94 B	\$2.65 - \$2.70	

Outlook: 2012 Guidance Summary

Q3 2012

- ☐ Adjusted EPS estimate range: \$0.62 \$0.64
 - ➢ Organic revenue growth of ~ 3%
 - Negative Fx impact of ~3% to sales (at June 30 rates)

FY 2012

- ☐ Adjusted EPS estimate range: \$2.65 \$2.70
 - Organic revenue growth ~ 4-5%
 - **→** Positive impact of 4% from acquisitions
 - **➢** Operating margin of ~18.5%
 - Negative Fx impact of ~2% to sales (at June 30 rates)
- **☐** Other modeling items
 - > Tax rate = ~30%
 - > Cap Ex ~\$40M
 - Free Cash Flow will exceed net income
 - Continued selective share repurchase
 - > EPS estimate excludes future restructuring, acquisitions and acquisition-related costs and charges

Q&A